EP2073634A4 - Stabilized prostaglandin e composition - Google Patents

Stabilized prostaglandin e composition

Info

Publication number
EP2073634A4
EP2073634A4 EP07839278A EP07839278A EP2073634A4 EP 2073634 A4 EP2073634 A4 EP 2073634A4 EP 07839278 A EP07839278 A EP 07839278A EP 07839278 A EP07839278 A EP 07839278A EP 2073634 A4 EP2073634 A4 EP 2073634A4
Authority
EP
European Patent Office
Prior art keywords
composition
stabilized prostaglandin
prostaglandin
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07839278A
Other languages
German (de)
French (fr)
Other versions
EP2073634A1 (en
Inventor
Daniel W Frank
Yiping Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring International Center SA
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of EP2073634A1 publication Critical patent/EP2073634A1/en
Publication of EP2073634A4 publication Critical patent/EP2073634A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07839278A 2006-10-11 2007-10-05 Stabilized prostaglandin e composition Withdrawn EP2073634A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/546,196 US7560489B2 (en) 2006-10-11 2006-10-11 Stabilized prostaglandin E composition
PCT/US2007/021374 WO2008045309A1 (en) 2006-10-11 2007-10-05 Stabilized prostaglandin e composition

Publications (2)

Publication Number Publication Date
EP2073634A1 EP2073634A1 (en) 2009-07-01
EP2073634A4 true EP2073634A4 (en) 2012-12-19

Family

ID=39283156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07839278A Withdrawn EP2073634A4 (en) 2006-10-11 2007-10-05 Stabilized prostaglandin e composition

Country Status (12)

Country Link
US (1) US7560489B2 (en)
EP (1) EP2073634A4 (en)
JP (1) JP5382800B2 (en)
KR (1) KR101400359B1 (en)
AU (1) AU2007307136B2 (en)
BR (1) BRPI0719228A2 (en)
CA (1) CA2665611C (en)
IL (1) IL197885A (en)
MX (1) MX2009003794A (en)
NZ (1) NZ576242A (en)
WO (1) WO2008045309A1 (en)
ZA (1) ZA200902467B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
PE20110849A1 (en) 2008-10-03 2011-12-02 Nexmed Holdings Inc STABILIZED COMPOSITION FOR THE TREATMENT OF PSORIASIS
CN104887388B (en) 2009-06-03 2018-01-09 弗赛特影像5股份有限公司 Anterior segment drug conveys
JP5864543B2 (en) 2010-05-04 2016-02-17 ネクスメッド ホールディングス，インコーポレイテッド Composition of small molecule therapeutic agent
MX336037B (en) * 2010-05-04 2016-01-07 Nexmed Holdings Inc Therapeutic peptide composition and method.
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
JP5989780B2 (en) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． Eye insertion device and method
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022310A1 (en) * 2001-09-06 2003-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20030129241A1 (en) * 1998-12-10 2003-07-10 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (en) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd Slow-releasing triple-layered film pharmaceutical containing prostaglandin and its preparation
US4806354A (en) * 1984-04-06 1989-02-21 Green James P Health food composition
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
GB2372213B (en) * 2000-11-17 2003-07-16 Icebella Enterpises Ltd Applicator and stimulator device
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
DE602004007315D1 (en) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilized pharmaceutical composition containing an NSAID and a prostaglandin
AR043476A1 (en) * 2004-09-09 2005-08-03 Dvoskin Victor Oscar REGULATED SUBSTANCE ADMINISTRATION DEVICE FOR INSERTION IN A BODY CAVITY AND PROCEDURE FOR MANUFACTURING A SUPPORT MEDIA FOR SUCH SUBSTANCES
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129241A1 (en) * 1998-12-10 2003-07-10 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
WO2003022310A1 (en) * 2001-09-06 2003-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008045309A1 *

Also Published As

Publication number Publication date
NZ576242A (en) 2012-04-27
EP2073634A1 (en) 2009-07-01
AU2007307136B2 (en) 2013-12-05
AU2007307136A1 (en) 2008-04-17
US7560489B2 (en) 2009-07-14
MX2009003794A (en) 2009-04-24
JP2010506831A (en) 2010-03-04
IL197885A (en) 2016-04-21
ZA200902467B (en) 2010-03-31
CA2665611A1 (en) 2008-04-17
CA2665611C (en) 2014-11-25
WO2008045309A1 (en) 2008-04-17
BRPI0719228A2 (en) 2015-02-03
KR20090064597A (en) 2009-06-19
US20080090911A1 (en) 2008-04-17
KR101400359B1 (en) 2014-06-19
IL197885A0 (en) 2009-12-24
JP5382800B2 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
GB0625586D0 (en) Composition
GB0607605D0 (en) Composition
ZA200902467B (en) Stabilized prostaglandin E composition
GB0624578D0 (en) Novel Composition
GB0623619D0 (en) Composition
GB0621329D0 (en) Novel composition
EP2059135A4 (en) New composition
GB0625430D0 (en) Composition
GB0625429D0 (en) Composition
GB0625841D0 (en) Composition
GB0623618D0 (en) Composition
PL379856A1 (en) Photopolymerizating composition
HK1119589A1 (en) Solid composition
GB0611175D0 (en) Composition
GB0615500D0 (en) Composition
GB0605984D0 (en) Composition
GB0607823D0 (en) Composition
GB0608658D0 (en) Composition
GB0622883D0 (en) Composition
GB0609701D0 (en) Composition
GB0605522D0 (en) Composition
GB0604896D0 (en) Composition
GB0612924D0 (en) Composition
GB0603790D0 (en) Composition
GB0613817D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/14 20060101ALI20121113BHEP

Ipc: A61K 47/18 20060101ALI20121113BHEP

Ipc: A61K 9/00 20060101ALI20121113BHEP

Ipc: A61K 31/19 20060101AFI20121113BHEP

17Q First examination report despatched

Effective date: 20140414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FERRING INTERNATIONAL CENTER S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190501